Dermatology

Psoriasis is a chronic, relapsing inflammatory skin disease, characterised in most cases by sharply demarcated, erythematous, pruritic plaques covered…

IL-23 plays a key regulatory role in the pathogenesis of plaque psoriasis and medications targeting IL-23 have been shown to be effective for people with…

Development of psoriasis occurs due to interactions with epidermal keratinocytes and immune-system cells including T-lymphocytes, antigen-presenting…

Psoriasis is associated with high morbidity, causing problems in daily life such as itching and scaling, even for patients with less-severe disease…

Allergies represent a significant, rising health concern. Recent figures indicate that 150 million Europeans experience chronic allergic disease…

The symposium “IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance” took place during the 2019 annual European Academy of Dermatology…

Guselkumab was the first monoclonal antibody targeting the p19 subunit of IL-23 (IL-23p19) to be approved for the treatment of psoriasis.

Prof Augustin opened the symposium by underlining how the management of patients with moderate-to-severe atopic dermatitis (AD) has become more dynamic…